Immunovant, Inc. (IMVT)Healthcare | Biotechnology | New York, United States | NasdaqGS
28.05 USD
-0.49
(-1.700%) ⇩
(April 21, 2026, 12:04 p.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:19 a.m. EDT
Despite a resilient recent price rally to year-to-date highs ($29.3), the instrumental data screams 'bottom fishing' or 'panic hedge' rather than a breakout. The crushing imbalance of option buying in the $20-$25 zone, combined with CEO insider selling and recent late-stage trial misses, indicates that smart money is preparing for a severe downside correction rather than a continuation of the current uptrend. The bullish price action is likely a trapped long trap for bull picks while short-sellers and hedging desks deploy at the top. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.039786 |
| AutoARIMA | 0.047701 |
| AutoETS | 0.049696 |
| MSTL | 0.050079 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 61% |
| H-stat | 1.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.711 |
| Excess Kurtosis | -0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 5,708,059,648 |
| Forward P/E | -10.86 |
| Beta | 0.67 |
| Website | https://immunovant.com |
As of April 19, 2026, 1:19 a.m. EDT: Immunovant exhibits extreme put put skew with massive open interest (OI) and volume concentrated in deep and out-of-the-money puts (e.g., $22, $23, $20 strikes) compared to the current $29.30 price. April data shows a 7.25 ATM IV for puts versus 1.28 for calls, indicating a distinct bearish hedge positioning by speculators. While there is notable OTM call volume at $30, it is significantly outweighed by the defensive put activity, suggesting traders are anticipating a decline or a sharp repricing of failure risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0021052 |
| Address1 | 320 West 37th Street |
| Address2 | 6th Floor |
| All Time High | 53.75 |
| All Time Low | 3.145 |
| Ask | 35.96 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,750,400 |
| Average Daily Volume3 Month | 1,386,262 |
| Average Volume | 1,386,262 |
| Average Volume10Days | 1,750,400 |
| Beta | 0.673 |
| Bid | 20.49 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 4.85 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.045 |
| Current Ratio | 15.741 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 28.69 |
| Day Low | 27.82 |
| Display Name | Immunovant |
| Earnings Call Timestamp End | 1,770,382,800 |
| Earnings Call Timestamp Start | 1,770,382,800 |
| Earnings Timestamp | 1,770,384,600 |
| Earnings Timestamp End | 1,779,971,400 |
| Earnings Timestamp Start | 1,779,971,400 |
| Ebitda | -486,751,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.886 |
| Enterprise Value | 4,812,248,064 |
| Eps Current Year | -2.59978 |
| Eps Forward | -2.5835 |
| Eps Trailing Twelve Months | -2.67 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 25.8542 |
| Fifty Day Average Change | 2.1907997 |
| Fifty Day Average Change Percent | 0.084736705 |
| Fifty Two Week Change Percent | 100.210526 |
| Fifty Two Week High | 29.48 |
| Fifty Two Week High Change | -1.4349995 |
| Fifty Two Week High Change Percent | -0.048677053 |
| Fifty Two Week Low | 13.36 |
| Fifty Two Week Low Change | 14.685 |
| Fifty Two Week Low Change Percent | 1.0991768 |
| Fifty Two Week Range | 13.36 - 29.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,561,123,800,000 |
| Float Shares | 77,464,348 |
| Forward Eps | -2.5835 |
| Forward P E | -10.855429 |
| Free Cashflow | -260,585,120 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 362 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.57273 |
| Held Percent Institutions | 0.54219 |
| Implied Shares Outstanding | 203,532,180 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,743,379,200 |
| Long Business Summary | Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. |
| Long Name | Immunovant, Inc. |
| Market | us_market |
| Market Cap | 5,708,059,648 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_592774643 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -464,199,008 |
| Next Fiscal Year End | 1,774,915,200 |
| Non Diluted Market Cap | 5,806,773,095 |
| Number Of Analyst Opinions | 17 |
| Open | 28.46 |
| Operating Cashflow | -422,888,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 917 580 3099 |
| Previous Close | 28.53 |
| Price Eps Current Year | -10.787451 |
| Price Hint | 2 |
| Price To Book | 5.7824745 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.035 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.4850006 |
| Regular Market Change Percent | -1.699967 |
| Regular Market Day High | 28.69 |
| Regular Market Day Low | 27.82 |
| Regular Market Day Range | 27.82 - 28.69 |
| Regular Market Open | 28.46 |
| Regular Market Previous Close | 28.53 |
| Regular Market Price | 28.045 |
| Regular Market Time | 1,776,787,480 |
| Regular Market Volume | 342,878 |
| Return On Assets | -0.41333 |
| Return On Equity | -0.69348 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 203,532,180 |
| Shares Percent Shares Out | 0.09060001 |
| Shares Short | 18,430,920 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 16,835,365 |
| Short Name | Immunovant, Inc. |
| Short Percent Of Float | 0.20709999 |
| Short Ratio | 14.23 |
| Source Interval | 15 |
| State | NY |
| Symbol | IMVT |
| Target High Price | 66.0 |
| Target Low Price | 22.0 |
| Target Mean Price | 40.29412 |
| Target Median Price | 42.0 |
| Total Cash | 994,524,992 |
| Total Cash Per Share | 4.886 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.739075 |
| Two Hundred Day Average Change | 6.3059254 |
| Two Hundred Day Average Change Percent | 0.2900733 |
| Type Disp | Equity |
| Volume | 342,878 |
| Website | https://immunovant.com |
| Zip | 10,018 |